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Real time in vivo detection of cellular senescence through the 
controlled release of the NIR fluorescent dye Nile Blue 
Beatriz Lozano-Torres,[a],[b],[c],[d],† Juan F. Blandez,[a],[b],[d],† Irene Galiana,[a],[b] Alba García-Fernández,[c] 
María Alfonso,[a] María D. Marcos,[a],[b],[c],[d] Mar Orzáez,[b],[e] Félix Sancenón,[a],[b],[c],[d]* and Ramón 
Martínez-Máñez[a],[b],[c],[d]*  
Abstract: In vivo optical detection of cellular senescence is 
accomplished by using mesoporous silica nanoparticles loaded with 
the NIR-FDA approved Nile Blue (NB) dye and capped with a 
galactohexasaccharide (S3). Emission at 672 nm of NB is highly 
quenched inside S3, yet a remarkable emission enhancement is 
observed upon cap hydrolysis in the presence of β-galactosidase 
and dye release. The efficacy of the probe to optically detect cellular 
senescence is tested in vitro in melanoma SK-Mel-103 and breast 
cancer 4T1 cells and in vivo in palbociclib-treated BALB/cByJ mice 
bearing breast cancer tumor.  
Cellular senescence is a stable state of cell cycle arrest 
necessary for maintaining the organism homeostasis.[1] However, 
the improper elimination of senescent cells, provokes local 
inflammation, tissue degeneration and contributes to aging.[2] 
Today scientific evidence supports that accumulation of 
senescent cells is involved in the pathophysiology of many age-
related diseases[3] and has boosted the concept that senescent 
cells is an attractive therapeutic target.[4,5] Recent reports, using 
in vivo models, evidence that a wide variety of diseases can be 
ameliorated by the elimination of senescent cells.[6,7] 
Characteristic signs of cellular senescence include 
changes in cell morphology,[8] the appareance of condensed 
nuclear chromatin foci, known as senescence-associated 
heterochromatic foci (SAHF).[9] and the overexpression or 
activation of tumor supressor proteins  such as p53, p16INK4a and 
p21 that contribute to cell cycle arrest.[10] Moreover, one of the 
most widely used markers to detect celular senescence is the 
overexpression of lysosomal β-galactosidase, also referred to as 
senescence-associated β-galactosidase (SA-β-Gal).[11] 
Measurement of SA-β-Gal activity using chromo-fluorogenic 
probes has become popular as an easy and simple procedure to 
detect senescence.[12,13] The use of molecularly imprinted 
nanopartilces has also been described recently for senescence 
detection.[14,15] However, most of the actual probes are suitable 
for in vitro studies, whereas probes to detect cellular 
senescence in vivo in realistic senescence models are scarce. 
One general drawback of most of these probes is that, even in 
realistic senescence models, detection is only posible after the 
animal sacrifice. Consequently, the development of  suitable 
methods for in vivo senescence detection remains an 
unresolved problem.[2]   
Based on the above, we report herein the use of 
nanoparticles[16] for in vivo detection of cellular senescence 
using a NIR fluorophore. The probe consists of 
galactohexasaccharide-capped mesoporous silica nanoparticles 
(MSNs) which are able to release their cargo in senescent cells 
due to the hydrolysis of the capping oligosaccharide by SA-β-
Gal.[17] We tested a number of fluorophores as cargo and finally 
selected Nile Blue (NB) due to its remarkable features as in vivo 
imaging agent. NB is an organic dye approved by the Food and 
Drug Administration (FDA) for human use[18] and it exhibits near 
infrared (NIR) emission at 672 nm.[19,20] Most importantly, NB is 
an aromatic planar fluorophore, which is highly quenched at high 
concentrations or in confined spaces as it forms non-emissive π-
stacked aggregates.[21]  
MSNs have been widely used as drug delivery systems 
due to their properties, such as biocompability and easy 
functionalization.[22] In addition to MSNs, other carriers for cargo 
delivery such as liposomes, micelles, polymers, etc have also 
been used in recent years.[23] In our case, MSNs were chosen as 
nanocarriers, due to their high loading capacity, allowing the NB 
dye to be entrapped at high concentration resulting in effective 
dye-dye π-stacking interactions and quenching. This compact 
packaging together with the gating capability exerted by the 
capping galactohexasaccharide (vide infra) would hardly be 
obtained using other nanocarriers. In fact, MSNs are well suited 
for the preparation of on-command delivery carriers by the 
functionalization of the outer surface with (bio)molecules that 
prevent payload release unless exposed to specific stimuli.[23] 
Besides, in MSN the cargo is simply encapsulated, while in 
some other nanoparticles cargo molecules need to be covalently 
linked. 
The prepared nanoparticles (i.e. S3 in Figure 1) are 
therefore poorly emissive, yet SA-β-Gal-induced hydrolysis of 
the capping hexagalacto-saccharide to give galactose residues, 
is expected to result in NB release, selectively inducing a 
marked NIR emission enhancement in senescent cells. 
Targeting of senescent cells in vitro with S3 is validated in SK-
Mel-103 (human melanoma) and 4T1 (murine breast cancer) cell 
lines treated with palbociclib. Moreover, in vivo detection of 
cellular senescence is demonstrated in BALB/cByJ mice bearing 
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breast cancer tumor treated with senescence-inducing 
chemotherapy.
Figure 1. Representation of S3 activation in BALB/cByJ female mice 
orthotopically injected with 4T1 cells to generate breast tumors. After tumor 
formation, mice were administered with palbociclib to generate senescence 
and treated with S3 achieving in vivo detection of cellular senescence. 
S3 is easily prepared from mesoporous silica 
nanoparticles,[24] which are loaded with NB, externally 
functionalized with APTES and finally capped with β(1,4)-
hexagalacto-saccharide (Scheme S1).The mesoporous structure 
in S3 and the starting mesoporous silica material (S0) was 
clearly observed by HR-TEM (Figure 2a, b and S1a) and by 
powder X-ray diffraction (Figure S1b). S3 was also characterized 
by porosimetry (Figure S2a, b and Table S1), ATR (Figure S3) 
and DLS (Figure S4). Moreover, from dye delivery experiments 
and thermogravimetric studies, the content of NB in S3 was 
determined to be 0.45 mmol g-1 of solid (Figure S5). 
Quenching of NB inside the pores of S3, was assessed. 
Free NB solutions presented much higher fluorescence than 
suspensions of S3, which showed negligible emission at 
equivalent NB concentrations (Figure 2c). Moreover, confocal 
images of S3 demonstrated that capped nanoparticles were 
poorly emissive (Figure S6). Quenching of NB at high 
concentrations was also studied in solution by monitoring the 
emission of the fluorophore at 666 nm (λexc = 635 nm) at 
different NB concentrations in water (pH = 4.5)-DMSO 99:1 v/v 
mixtures. Emission of NB solutions increased until a 
concentration of ca. 1.0 x 10-4 M, whereas at higher 
concentrations the fluorescence decreased. In fact, NB 
concentrations higher than 10-3 M are poorly emissive (Figure 
2d). From the amount of NB loaded and the specific pore 
volume in S3 a molar concentration of the dye in the pores of ca. 
0.49 M was calculated which is in agreement with the low 
emission observed for S3 in Figure 2c.  
Figure 2. (a) HR-TEM images of S3, (b) TEM-EDX of S3. (c) Fluorescence of 
a NB solution (1.81 x 10
-4
 M) and of S3 suspensions at equivalent 
concentrations of the dye. (d) Emission intensity of NB solutions vs 
fluorophore concentration. (e) Release profile of S3 in the absence (grey line) 
and in the presence of β-Gal (black line). Experiments were carried out in 
water-DMSO 99:1 v/v mixtures at pH 4.5. Error bars are expressed as 3σ 
Delivery of NB from S3 was studied in the presence and in 
the absence of β-Gal enzyme (Figure 2e). S3 show a marked 
NB delivery in the presence of β-Gal of ca. 90% of the maximum 
dye released after 24 h, which corresponded to 31.4 % (5.69 x 
10-5 M) of the dye entrapped (Figure S7). In contrast a low NB 
release in the absence of β-Gal was found. Release in the 
presence of β-Gal is due to the hydrolysis of glycosidic bonds in 
the capping galacto-saccharide which reduced steric crowding 
around the pores allowing NB delivery.  
Specific targeting of senescent cells in vitro with S3 was 
demonstrated in SK-Mel-103 (human melanoma) and 4T1 
(murine breast cancer) cells treated with 5 µM palbociclib (a 
CDK4/6 inhibitor which suppresses DNA replication inducing cell 
cycle arrest) for two weeks to induce senescence. Senescence 
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Figure 3. (a,e,i,m) X-Gal assay for detection of SA-β-Gal expression in (a) control and (e) senescent SK-Mel-103 cells and in (i) control 4T1 and (m) senescent 
4T1 cells. (b,c) Confocal images of control SK-Mel-103 cells (b) in the absence or (c) in the presence of S3. (f,g) SK-Mel-103 cells treated with palbociclib (f) in the 
absence (g) or in the presence of S3. (d,h) Confocal images of (d) control SK-Mel-103 cells or (h) SK-Mel-103 cells treated with palbociclib in the presence of 
equivalent doses of free NB. (j,k) Confocal images of control 4T1 cells (j) in the absence or (k) in the presence of S3. (n,o) 4T1 cells treated with palbociclib (n) in 
the absence (o) or in the presence of S3. (l,p) Confocal images of (l) control 4T1 cells or (p) 4T1 treated with palbociclib in the presence of equivalent doses of 
free NB. Cells were incubated with S3 (7.8 µg/ml) for 4.5 h in DMEM (10% FBS) in 20% O2 and 5% CO2 at 37°C, washed three times and stained with Hoechst 
(1.5 ng/ml) for 15 min. Confocal images were acquired by using confocal microscope (Leica TCS SP8 AOBS). Representative images from repeated experiments 
(n=3) are shown. (q) Quantification of fluorescence emission ascribed to released NB in control and palbociclib-treated SK-Mel-103 cells incubated with S3 and 
quantification of fluorescence emission upon treatment with equivalent doses of free NB. Autofluorescence is the emission observed in SK-Mel-103 cells without 
treatment with S3 or free NB. (r) Quantification of fluorescence emission ascribed to released NB in control and palbociclib-treated 4T1 cells incubated with S3 
and quantification of fluorescence emission upon treatment with equivalent doses of free NB. Autofluorescence is the emission observed in 4T1 cells without 
treatment with S3 or free NB. Error bars represent s.d. 
Confocal microscopy studies of palbociclib-treated SK-
Mel-103 and 4T1 cells, incubated with S3,  revealed an intense 
fluorescent signal (Figure 3g and 3o), whereas non-senescent 
SK-Mel-103 and 4T1 cells treated with S3 presented weak 
fluorescence (Figure 3c and 3k). Both control and senescent 
SK-Mel-103 and 4T1 cells showed also negligible background 
(Figures 3b, 3f, 3j and 3n respectively). In addition, it was found 
that control and senescent cells treated with equivalent doses 
of free NB presented nearly the same fluorescence (Figures 3d, 
3h, 3l and 3p, see also Figure S8). Quantification of 
fluorescence showed 7-fold emission enhancement in 
senescent SK-Mel-103 cells treated with S3 compared to 
controls (Figure 3q). For the 4T1 cell line, the emission 
enhancement of senescent cells tretaed with S3 when 
compared to control 4T1 cells was 10-fold. Results are 
indicative of S3 uptake and galacto-oligosacchadride hydrolysis 
by SA-β-Gal in senescent cells, resulting in NB release. 
Moreover it was found that S3 nanoparticles were not toxic for 
both control and senescent cells (Figure S9). 
In vivo detection of celular senescence with S3 was 
validated in mice bearing breast tumors treated with 
senescence-inducing chemotherapy. For this purpose, 
BALB/cByJ female mice were orthotopically injected with 4T1 
(mouse mammary carcinoma) cells (0.5 x 106 cell/mouse) to 
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Figure 4. (a) IVIS images at different time points of BALB/cByJ female mice bearing 4T1 breast tumor. From left to right control mice treated with S3 (two mice 
from group B) and BALB/cByJ mice treated by oral gavage with palbociclib (senescent tumors) for 1 week and intravenously injected with S3 (two mice from 
group D). (b) Quantification of fluorescence emission intensity from tumor signals with time. Error bars represent s.d. (c) X-Gal assay for SA-β-Gal expression in 
tumors from control group A (up) and palbociclib-treated group C (bottom). (i,ii, iii,iv) IVIS images of organs and tumors from BALB/cByJ female mice bearing 4T1 
breast tumor. From left to right and from top to bottom: lungs, liver, tumor, kidney and spleen. (i) Control mice (group A). (ii) Control mice treated with S3 (group B, 
4 mg/ml 200 µl). (iii) BALB/cByJ female mice bearing 4T1 breast tumor treated oral gavage with palbociclib for 1 week (group C). (iv) Palbociclib-treated mice 
intravenously injected with S3 (group D, 4 mg/ml 200 µl). Mice were sacrificed 24 h post-treatment for these images. (d) Quantification of fluorescence emission 
from organs and tumors in i,ii,iii and iv images. Error bars represent s.d. 
Mice were divided into four groups: (A) control individuals with 
4T1 tumors; (B) control individuals with 4T1 tumors administered 
with S3; (C) mice only administered with palbociclib; and (D) 
individuals with 4T1 tumors treated with palbociclib and S3. 
Groups C and D were daily treated by oral gavage with 
palbociclib after tumor development to induce sensecence and 
arrest of tumor growth. Once completed 7 days of palbociclib 
treatment, S3 nanoparticles were intravenously administered to 
groups B and D, and mice were monitored by an in vivo imaging 
system (IVIS) at different time points for 48 h. No 
autofluorescence was observed from control (A) and palbociclib 
(C) treated mice (Figure S10). Mice from groups A, B and C 
showed negligible fluorescence in the tumor area, while a strong 
fluorescent signal was observed for group D, which was 
administered both with palbociclib and S3 (Figure 4a). The peak 
of maximum fluorescence in mice treated with palbociclib and 
S3 (group D) was observed 24-36 h post-injection of the 
nanoparticles (Figure 4a), whereas a clear decrease in the 
fluorescence signal was found at 48 h. Quantification of the 
relative values of radiance (p/s/cm2/sr x 1010) showed and 
enhancement of 4.3 fold at 24 h and 7.3 fold at 36 h in 
palbociclib+S3 treated mice when compared to vehicle ones 
(Figure 4b). 
Mice were euthanized and blood, lungs, liver, kidney, 
spleen and tumors were ex vivo analyzed. Senescence in 
tumors from mice treated with palbociclib was confirmed by X-
Gal staining (Figure 4c) and reduced immunostaining of the Ki67 
proliferation marker indicative of cell cycle arrest (Figure S11). 
IVIS images o excised organs and tumors from vehicle (A) or 
palbociclib-treated mice (C) did not show any fluorescence 
(Figures 4c, i) and iii)). Similarly, tumors from vehicle mice 
injected with S3 (B) did not show any noticeable fluorescent 
signal (Figure 4c, ii)). In contrast, strong emission (ca. 17.6 fold) 
was observed in tumors from mice treated with palbociclib and 
intravenously injected with S3 (Figure 4c, iv and Figure 4d). 
Biodistribution of nanoparticles was studied by determining 
silicon levels in various organs by inductively coupled plasma 
mass spectroscopy (ICP-MS) (Figure S12). Nanoparticles reach 
both senescent and non-senescent tumors at 24 h whereas 
levels of Si are significantly reduced 48 h post-injection, which is 
consistent with the patterns of fluorescence signal (vide ante). 
S3 also acumulated in spleen, lungs and kidney at 24 h, 














































































































48 h. Note that even though some mesoporous silica 
nanoparticles accumulate in liver, spleen or kidney, negligible 
fluorescence was detected in these organs 24 h post injection. 
This is due to the very low emission from the capped S3 (due to 
π-stacking NB interactions in the pores) and also indicates that 
nanoparticles remain capped in these organs which did not 
overexpress SA-β-Gal enzyme. Blood biochemistry and 
hematology analysis of different paremeters, such as albumin 
(ALB), bilirubin (BIL), alkaline phosphatase (AKP), glutamic 
pyruvic transaminase (GPT) and aspartate transaminase (GOT), 
showed no noticeable signs of organ damage and systemic 
inflammatory response after nanoparticles administration (B and 
D) when compared to S3 untreated (A and C) groups (Figure
S13). 
As summary, we describe here MSN loaded with NB dye 
and capped with a galacto-oligosaccharide for the in vivo 
detection of cellular senescence. S3 nanoparticles are poorly 
emissive due to π-stacking interactions of NB molecules densely 
packed onto the mesopores, yet NB is selectively released in 
senescent cells resulting in a marked emission enhancement. In 
vitro targeting of senescent cells with S3 was validated in SK-
Mel-103 and 4T1 cells treated with palbociclib. A remarkable 
enhanced emission in palbociclib-treated SK-Mel-103 and 4T1 
senescent cells was observed when incubated with S3 in 
comparison with control cells. S3 was validated in vivo in 
BALB/cByJ female mice orthotopically injected with 4T1 cells to 
generate breast tumors and treated with palbociclib. In vivo IVIS 
images showed a remarkable emission enhancement (4.3 fold at 
24 h and 7.3 fold at 36 h) in tumors from mice treated with 
palbociclib and intravenously injected with S3, whereas 
negligible signal was found in mice only treated with S3 and in 
palbociclib-treated mice without S3 administration. In good 
accordance, ex vivo IVIS images showed that fluorescence 
ascribed to NB was only observed in senescent tumors (17.6-
fold enhancement) but not in control tumors or other organs. The 
performance in terms of selectivity and sensitivity makes S3 and 
efficient OFF-ON probe for the in vivo detection of senescence. 
We anticipate that this or similar probes able to detect cellular 
senescence in vivo will become essential tools to follow 
treatment response and efficacy of senotherapies in a wide 
range of aged-related diseases. 
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